H.C. Wainwright Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Raises Target Price to $18
Craig-Hallum Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Announces Target Price $10
Piper Sandler Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Maintains Target Price $10
Cardiff Oncology Is Maintained at Buy by HC Wainwright & Co.
Cardiff Oncology Analyst Ratings
Express News | Cardiff Oncology, Inc. : H.c. Wainwright Raises Target Price to $18 From $17
Cardiff Oncology's Strategic Advances in Cancer Treatment: A Compelling Buy Opportunity
TD Cowen Maintains Cardiff Oncology(CRDF.US) With Buy Rating
Cardiff Oncology Reports Q1 EPS (20c), Consensus (19c)
Cardiff Oncology | 8-K: Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update
Express News | Cardiff Oncology Q1 Income From Operations USD -14.382 Million Vs. IBES Estimate USD -13.5 Million
Express News | Cardiff Oncology Q1 Operating Expenses USD 14.491 Million
Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update
Cardiff Oncology 1Q Loss/Shr 20c >CRDF
Cardiff Oncology | 10-Q: Q1 2025 Earnings Report
William Blair Maintains Cardiff Oncology(CRDF.US) With Buy Rating
Promising Developments in Cardiff Oncology's Cancer Treatment Boost Buy Rating
Cardiff Oncology Announces Second Patent for Onvansertib Combination
Express News | Cardiff Oncology Announces a Second Patent for the Treatment of Mcrc for Bev-Naïve Patients
Craig-Hallum Maintains Cardiff Oncology(CRDF.US) With Buy Rating